文献速递肾小球疾病

双硫仑抑制趋化因子信号调节蛋白FROUNT改善新月体性肾小球肾炎

Inhibition of the chemokine signal regulator FROUNT by disulfiram ameliorates crescentic glomerulonephritis.
PubMed 文献 · Kidney Int · 2022-08-30

本研究在大鼠抗肾小球基底膜(GBM)肾小球肾炎模型中证实,双硫仑在人等效剂量下可阻断白蛋白尿、新月体形成及后期肾脏纤维化病变,其衍生物DSF-41在更低剂量下即抑制肾炎;机制涉及抑制单核/巨噬细胞趋化及活化,人抗GBM肾炎新月体肾小球中亦见FROUNT表达。

要点

  • 双硫仑在人等效剂量下阻断大鼠抗GBM肾炎的白蛋白尿、新月体形成及后期纤维化。
  • 衍生物DSF-41的FROUNT抑制活性更强,在更低剂量下即抑制肾小球肾炎。
  • 双硫仑减少早期单核/巨噬细胞数量及建立期CD3+和CD8+淋巴细胞数量。

核心结论

  • 双硫仑可通过阻断肾小球内单核/巨噬细胞的趋化反应及活化状态,成为治疗肾小球肾炎的高效且安全的药物。

研究设计与样本

  • 研究采用大鼠抗GBM肾小球肾炎模型,并进行体外骨髓来源单核/巨噬细胞实验及人抗GBM肾炎肾组织FROUNT表达观察。

主要发现

  • 双硫仑在人等效剂量下成功阻断大鼠抗GBM肾炎的白蛋白尿、伴足细胞丢失的新月体形成及后期肾脏纤维化病变。
  • 衍生物DSF-41的FROUNT抑制活性更强,在比双硫仑更低的剂量下抑制肾小球肾炎。
  • 双硫仑明显减少肾炎早期单核细胞或巨噬细胞数量,以及建立期CD3+和CD8+淋巴细胞数量。
  • 双硫仑组肾小球单核/巨噬细胞伪足形成受损,与体外双硫仑阻断趋化因子依赖性伪足形成及骨髓来源单核/巨噬细胞趋化的观察一致。
  • 双硫仑抑制巨噬细胞活化,表现为促炎细胞因子和趋化因子(TNF-α、CCL2和CXCL9)表达降低及单核/巨噬细胞CD86和MHC II类表达减少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Activated monocytes/macrophages promote glomerular injury, including crescent formation, in anti-glomerular basement membrane (GBM) glomerulonephritis. Disulfiram, an alcohol-aversion drug, inhibits monocyte/macrophage migration by inhibiting FROUNT, a cytosolic protein that enhances chemokine receptor signaling. Our study found that disulfiram at a human equivalent dose successfully blocked albuminuria and crescent formation with podocyte loss, and later stage kidney fibrotic lesions, in a rat model of anti-GBM glomerulonephritis. A disulfiram derivative, DSF-41, with more potent FROUNT inhibition activity, inhibited glomerulonephritis at a lower dose than disulfiram. Disulfiram markedly reduced the number of monocytes or macrophages at the early stage of glomerulonephritis and that of CD3+ and CD8+ lymphocytes at the established stage. Impaired pseudopodia formation was observed in the glomerular monocytes/macrophages of the disulfiram group; consistent with the in vitro observation that disulfiram blocked chemokine-dependent pseudopodia formation and chemotaxis of bone marrow-derived monocytes/macrophages. Furthermore, disulfiram suppressed macrophage activation as revealed by reduced expression of inflammatory cytokines and chemokines (TNF-α, CCL2, and CXCL9) and reduced CD86 and MHC class II expressions in monocytes/macrophages during glomerulonephritis. The dramatic reduction in monocyte/macrophage number might have resulted from disulfiram suppression of both the chemotactic response of monocytes/macrophages and their subsequent activation to produce cytokines and chemokines, which further recruit monocytes. Additionally, FROUNT was expressed in CD68+ monocytes/macrophages infiltrating the crescentic glomeruli in human anti-GBM glomerulonephritis. Thus, disulfiram can be a highly effective and safe drug for the treatment of glomerulonephritis by blocking the chemotactic responses of monocytes/macrophages and their activation status in the glomerulus.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Toda E, Sawada A, Takeuchi K, et al. Inhibition of the chemokine signal regulator FROUNT by disulfiram ameliorates crescentic glomerulonephritis. Kidney Int. 2022. PMID: 36049642. doi:10.1016/j.kint.2022.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。